DW10075 is a highly selective VEGFR inhibitor that targets the VEGF/VEGFR signaling pathway, demonstrating potent anti-angiogenic activity for cancer therapy; it selectively inhibits VEGFR-1, VEGFR-2, and VEGFR-3 without affecting other kinases such as FGFR and PDGFR; it suppresses VEGF-induced proliferation, migration, and tube formation of human umbilical vein endothelial cells (HUVECs); it inhibits angiogenesis in rat aortic ring and chick chorioallantoic membrane models; it exhibits antiproliferative activity against a panel of 22 human cancer cell lines; and it significantly inhibits tumor growth and reduces CD31 and Ki67 expression in tumor tissues in a U87-MG xenograft mouse model, highlighting its potential as an anti-tumor angiogenesis agent worthy of further development.